Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics (NQ: FOLD )

12.81 +0.19 (+1.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,637,059
Open 12.61
Bid (Size) 12.55 (1)
Ask (Size) 13.00 (5)
Prev. Close 12.62
Today's Range 12.52 - 12.92
52wk Range 7.780 - 13.84
Shares Outstanding 266,555,274
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark
One key metric to look for in a stock is an 80-plus RS Rating. Amicus Therapeutics stock hit that mark, with a jump from 74 to 82 Friday. 
Via Investor's Business Daily
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult  
Via Benzinga

Performance

YTD
+7.38%
+7.38%
1 Month
+10.62%
+10.62%
3 Month
+11.98%
+11.98%
6 Month
+9.53%
+9.53%
1 Year
+49.82%
+49.82%

More News

Read More
Amicus Therapeutics: Q1 Earnings Insights
Via Benzinga
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Amicus Therapeutics
Via Benzinga
Earnings Scheduled For March 1, 2023
Via Benzinga
Earnings Preview: Amicus Therapeutics
Via Benzinga
Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past Month
Via Benzinga
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Recap: Amicus Therapeutics Q3 Earnings
Via Benzinga
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.